Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
Recruiting · NCT03104491 · Registry updated 2026-09-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-09-10 | NCT03104491 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Leland Metheny | 2 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center | Cleveland | United States | 20 |
| Dana-Farber Cancer Institute | Boston | United States | 626 |
| Memorial Sloan Kettering Cancer Center | New York | United States | 1000 |
| The James Cancer Hospital and Solove Research Institute | Columbus | United States | 10 |
| The University of Kansas Cancer Center | Westwood | United States | 31 |
| University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center | Cleveland | United States | 4 |
| University of Nebraska Medical Center | Omaha | United States | 11 |